Clinical trial
CP-609,754 in Treating Patients With Advanced Solid Tumors
NCT00006085 · H. Lee Moffitt Cancer Center and Research Institute, Other · Unknown status
Key facts
| NCT number | NCT00006085 |
|---|---|
| Title | CP-609,754 in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Open-Label Study of the Safety, Toleration and Pharmacokinetics of CP-609,754, a Farnesyl Transferase Inhibitor, in Subjects With Advanced Malignant Tumors |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | CP-609, 754 |
| Start date | Jun 1, 2000 |
| First posted | Mar 16, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: